In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
In the latest session, Carisma Therapeutics Inc (NASDAQ: CARM) closed at $0.40 down -16.54% from its previous closing price of $0.49. In other words, the price has decreased by -$16.54 from its previous closing price. On the day, 0.58 million shares were traded. CARM stock price reached its highest trading level at $0.4796 during the session, while it also had its lowest trading level at $0.4008.
Ratios:
For a deeper understanding of Carisma Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.23 and its Current Ratio is at 3.23.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Robert W. Baird on December 12, 2024, Downgraded its rating to Neutral and sets its target price to $1 from $10 previously.
On April 11, 2024, BTIG Research started tracking the stock assigning a Buy rating and target price of $6.BTIG Research initiated its Buy rating on April 11, 2024, with a $6 target price.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CARM now has a Market Capitalization of 16900440 and an Enterprise Value of -7911556. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.70. Its current Enterprise Value per Revenue stands at -0.39 whereas that against EBITDA is 0.125.
Stock Price History:
The Beta on a monthly basis for CARM is 1.53, which has changed by -0.8578947 over the last 52 weeks, in comparison to a change of 0.2764505 over the same period for the S&P500. Over the past 52 weeks, CARM has reached a high of $3.16, while it has fallen to a 52-week low of $0.46. The 50-Day Moving Average of the stock is -55.16%, while the 200-Day Moving Average is calculated to be -68.86%.
Shares Statistics:
For the past three months, CARM has traded an average of 174.35K shares per day and 406190 over the past ten days. A total of 41.75M shares are outstanding, with a floating share count of 21.84M. Insiders hold about 47.70% of the company’s shares, while institutions hold 11.18% stake in the company. Shares short for CARM as of 1732838400 were 554174 with a Short Ratio of 3.18, compared to 1730332800 on 857538. Therefore, it implies a Short% of Shares Outstanding of 554174 and a Short% of Float of 1.66.
Earnings Estimates
As of right now, 3.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is -$0.18, with high estimates of -$0.08 and low estimates of -$0.28.
Analysts are recommending an EPS of between -$1.16 and -$1.32 for the fiscal current year, implying an average EPS of -$1.23. EPS for the following year is -$0.54, with 3.0 analysts recommending between -$0.29 and -$1.0.
Revenue Estimates
A total of 4 analysts believe the company’s revenue will be $5.42M this quarter.It ranges from a high estimate of $8M to a low estimate of $3.38M. As of the current estimate, Carisma Therapeutics Inc’s year-ago sales were $4.29MFor the next quarter, 4 analysts are estimating revenue of $4.69M. There is a high estimate of $6M for the next quarter, whereas the lowest estimate is $3.38M.
A total of 4 analysts have provided revenue estimates for CARM’s current fiscal year. The highest revenue estimate was $24M, while the lowest revenue estimate was $19.36M, resulting in an average revenue estimate of $21.41M. In the same quarter a year ago, actual revenue was $14.92MBased on 4 analysts’ estimates, the company’s revenue will be $20.32M in the next fiscal year. The high estimate is $25M and the low estimate is $14.59M.
